Biora Therapeutics, Inc.

Biora Therapeutics, Inc.

BIORQ

BIORQBiora Therapeutics, Inc. US flag

Other OTC

0.00

USD

- -

- -

905.00Market Cap

Biora Therapeutics, Inc.

BIORQ

(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Pathfinder Cell Therapy, Inc. (PFND)
Viking Therapeutics, Inc. (VKTX)
Synairgen plc (SYGGF)
CNBX Pharmaceuticals Inc. (CNBX)
NextCure, Inc. (NXTC)
SL Science Holding Ltd (SLBT)
Business: Biora Therapeutics, Inc. (BIORQ) is a clinical-stage biotechnology company focused on developing oral biotherapeutics through innovative targeted drug delivery platforms. The company offers NaviCap, a targeted oral delivery platform designed for site-specific delivery of therapeutics in the gastrointestinal tract to enhance treatment of inflammatory bowel diseases such as ulcerative colitis; and BioJet, a systemic oral delivery platform engineered to replace injections with needle-free, oral administration of large-molecule biologics for chronic disease management. Founded in 2010 and headquartered in San Diego, California, Biora Therapeutics operates primarily in the United States within the biotechnology sector, targeting pharmaceutical collaborators and patients with gastrointestinal and chronic systemic conditions. In recent developments, the company secured a $16 million multiple-draw funding facility from existing convertible noteholders in August 2024 to bridge to anticipated pharmaceutical partnerships, driven by active interest in its BioJet platform and promising NaviCap clinical trial results. It advanced its BioJet platform in October 2024, announcing progress toward a smaller 00-size device demonstrating over 30% oral bioavailability in more than 30 in vivo studies, as presented at the 14th Annual Partnerships in Drug Delivery meeting. However, Biora Therapeutics filed for voluntary Chapter 11 reorganization on December 27, 2024, in the U.S. Bankruptcy Court for the District of Delaware, which was converted to Chapter 7 liquidation on May 27, 2025, marking a significant operational shift. Formerly known as Progenity, Inc., it rebranded to Biora Therapeutics in April 2022 to align with its therapeutics pipeline focus.

Company News